Durvalumab cuts NSCLC relapse; interim OS not significant

Editor's Pick: Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial (Journal of Clinical Oncology, 2026)
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning perioperative and late-line immunotherapy, the shifting genomic and treatment landscape of colorectal cancer, and the whole-patient side of our specialty — cardiovascular risk, treatment of older adults, and the economics of biosimilars. Let's dive in.

We start with perioperative immunotherapy in lung cancer.
This week's papers:
• Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42664473)
• Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42659588)
• Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42663536)
• Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial — JAMA Internal Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42669035)
• Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42659576)
• A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42658187)
• L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial — Nature Cancer 2026 (pubmed.ncbi.nlm.nih.gov/42675216)
• Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42658515)
• Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer — Cancer Cell 2026 (pubmed.ncbi.nlm.nih.gov/42679811)
• Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42658505)
Listen at AudioScholar (audioscholar.cc/episode/tseu78stmg)